Cancer drugs lead pharma earnings

Studies anticipate that cancer drug sales will reach $311 billion annually by 2031, with these medicines approaching a 20% share of the global pharmaceutical market. This growth comes amid rising cancer treatment costs, which exceed $100,000 per patient, and increasing incidence rates as life expectancy rises. Additionally, investments in cancer research and the development of new medications contribute to this growth, although they also raise treatment costs due to the high prices set by pharmaceutical companies for the latest drugs.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل